Intravenous immunoglobulin treatment for refractory pyoderma gangrenosum.
Jacqueline K NguyenZachary HolmesRobert I KellyPublished in: The Australasian journal of dermatology (2023)
Our experience suggests that IVIG may be an efficacious treatment for patients with refractory PG due to its pleiotropic and immunomodulatory effects, particularly for patients with malignancy or other systemic conditions where high-dose immunosuppressive agents are contraindicated.